Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 19 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 11034736

    Anti-viral cnidarins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  2. US 11014983

    Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies

    Sutro Biopharma, Inc. · Granted May 25, 2021 · Expires May 20, 2041

    granted

  3. US 10995150

    Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted

  4. US 10981977

    Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis

    THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  5. US 10983128

    CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

    Providence Health & Services · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  6. US 10980780

    Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases

    NEUROSENSE THERAPEUTICS LTD. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  7. US 10975158

    CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  8. US 10975150

    Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies

    Sutro Biopharma, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  9. US 10975139

    Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  10. US 10966977

    Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders

    TG Therapeutics, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted

  11. US 10961305

    Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

    Mereo Biopharma 3 Limited · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  12. US 10961301

    Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair

    The United States Government represented by the Department of Veterans Affairs · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  13. US 10954289

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

  14. US 10947310

    Fusion protein comprising apelin and an anti-APLNR antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  15. US 10947198

    Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents

    The Board of Regents for Oklahoma State University · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  16. US 10941210

    Anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted

  17. US 10941208

    Anti-MUC16 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted

  18. US 10941213

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted

  19. US 10934337

    Anti-BCMA chimeric antigen receptors

    Cartesian Therapeutics, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  20. US 10934349

    Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  21. US 10925923

    Peptide having anti-inflammatory activity, and use thereof

    CAREGEN CO., LTD. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted

  22. US 10925969

    Anti-BCMA polypeptides and proteins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted

  23. US 10913785

    Anti-human papillomavirus 16 E6 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted

  24. US 10905784

    Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.